Can a new drug boost chemotherapy against mysterious cancers?

NCT ID NCT07761429

Recruiting now Disease control Sponsor: Shandong New Time Pharmaceutical Co., LTD Source: ClinicalTrials.gov ↗

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial is testing whether adding an experimental drug called F520 to standard chemotherapy (paclitaxel plus carboplatin) helps people with cancer of unknown primary — a cancer that has spread but whose original site cannot be found. About 402 adults aged 18 to 75 who have not had prior systemic therapy will be randomly assigned to receive either the F520 combination or a placebo with chemotherapy. The study measures how well the tumors shrink, how long people live without the cancer progressing, and overall survival, while also tracking side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: F520 combined with paclitaxel and carboplatin
What this could lead to: If effective, this combination could become a new first-line treatment option for people with cancer of unknown primary, potentially slowing tumor growth and extending life.
What could go wrong: This is an early-to-mid-stage trial, so the added benefit of F520 is uncertain. It may not improve outcomes and could increase side effects compared to chemotherapy alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER OF UNKNOWN PRIMARY SITE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer of unknown primary site Neoplasms, Unknown Primary

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER OF UNKNOWN PRIMARY SITE

Contacts and locations

Locations

Shanghai tumor hospital
RECRUITING

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.